Trastuzumab Emtansine

證據等級: L5

預測適應症: 4 個

Trastuzumab Emtansine: From HER2-Positive Breast Cancer to Progesterone-Receptor Positive Breast Cancer

One-Sentence Summary

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate originally developed and used for HER2-positive breast cancer, combining the anti-HER2 antibody trastuzumab with the cytotoxic payload DM1. The TxGNN model predicts it may also be effective for Progesterone-Receptor Positive Breast Cancer, with 4 clinical trials and 15 publications currently retrieved in support of this direction — though, as discussed below, several of these overlap with the drug’s already-established HER2-positive population rather than representing a wholly independent disease target.

Quick Overview

Item	Content
Original Indication	HER2-positive breast cancer (established global indication for T-DM1/Kadcyla; no formal local approved-indication text is available because the drug is not currently marketed in this jurisdiction)
Predicted New Indication	Progesterone-Receptor Positive Breast Cancer
TxGNN Prediction Score	99.82%
Evidence Level	L3
US Market Status	✗ Not Marketed
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DrugBank MOA field is a data gap). Based on known information, trastuzumab emtansine is an antibody-drug conjugate (ADC) that couples trastuzumab, an antibody targeting HER2, with DM1, a cytotoxic maytansinoid microtubule inhibitor. Upon binding to HER2-overexpressing tumor cells, the conjugate is internalized and releases DM1 intracellularly, producing a targeted cytotoxic effect. Its efficacy in HER2-positive breast cancer is well established through numerous completed Phase 2/3 trials.

Progesterone-receptor (PR) status is a separate biomarker from HER2 amplification, and a substantial proportion of HER2-positive breast cancers are also hormone-receptor (HR/PR) positive. Anti-HER2 therapies, including T-DM1, are already used in this HR+/HER2+ overlap population regardless of PR status — meaning the TxGNN prediction likely reflects a real, mechanistically grounded overlap rather than an entirely novel disease indication. This is consistent with the underlying mechanism: HER2 expression, not PR status, determines eligibility for T-DM1 binding and cytotoxic delivery.

That said, the retrieved evidence should be interpreted with caution. Of the four clinical trials returned, only two (NCT02326974, NCT04675827) actually administer T-DM1; one (NCT06131424) is a retrospective observational registry on HER2-low disease unrelated to PR status; and one Phase 3 trial (NCT03726879) does not include T-DM1 in its treatment arms at all. This suggests the automated evidence match was driven largely by shared “HER2-positive breast cancer” terminology rather than PR-specific outcome data, and the evidence base should be manually re-curated before advancing beyond an early evaluation stage.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02326974	Phase 2	Active, not recruiting	164	Evaluates T-DM1 + pertuzumab in the preoperative setting for early-stage HER2-positive breast cancer, examining impact of HER2 heterogeneity on response
NCT04675827	Phase 2	Terminated	139	De-escalation study of neoadjuvant chemotherapy + dual HER2 blockade in HER2-positive, ER-negative, node-negative early breast cancer achieving pathological complete response
NCT06131424	N/A (observational)	Completed	1,151	Retrospective study on prevalence and treatment patterns of HER2-low metastatic breast cancer; not specific to PR status or T-DM1 use
NCT03726879	Phase 3	Completed	454	IMpassion050: atezolizumab vs placebo with neoadjuvant chemo + trastuzumab + pertuzumab in early HER2-positive breast cancer — does not include T-DM1 as a study arm

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35640077	2022	Guideline/Review	J Clin Oncol	ASCO guideline update on systemic therapy for advanced HER2-positive breast cancer, encompassing HR+ and HR- subgroups
29939838	2018	Guideline/Review	J Clin Oncol	ASCO clinical practice guideline update on systemic therapy for advanced HER2-positive breast cancer
24799465	2014	Guideline/Review	J Clin Oncol	ASCO clinical practice guideline for advanced HER2-positive breast cancer, first establishing T-DM1’s role in later-line therapy
28259011	2017	Guideline/Review	Eur J Cancer	EGTM biomarker guideline confirming ER/PR and HER2 as co-determinants for selecting anti-HER2 therapy, including T-DM1
39631485	2024	Review	Pharmacological Research	Reviews targeted and cytotoxic inhibitors in breast cancer, discussing HER2/HR-stratified management
33726508	2021	Review	Future Oncology	Reviews current treatment trends in HR+/HER2+ breast cancer, explicitly discussing T-DM1’s role in this overlapping subgroup
34215766	2021	Cohort/Real-world	Scientific Reports	ChangeHER trial data on prognostic relevance of HER2-positivity gain in metastatic breast cancer treated with pertuzumab/T-DM1
35251981	2022	Case Report	Frontiers in Oncology	Case report on pyrotinib + metronomic vinorelbine in HER2-positive breast cancer with leptomeningeal disease
40642740	2025	Case Report	J Medical Cases	Long-term follow-up case of durable response with trastuzumab deruxtecan in HER2-mutated metastatic breast cancer
25873876	2015	Case Report	Case Reports in Oncology	Dose-reduced T-DM1 shown to be active and safe in a patient with acute hepatic dysfunction

US Market Information

This drug is not currently marketed in this jurisdiction (0 licenses on record); no authorization or approved-indication text is available to summarize.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (HER2-targeted antibody-drug conjugate with cytotoxic maytansinoid [DM1] payload)
Myelosuppression Risk	Medium — thrombocytopenia is the most characteristic hematologic toxicity of T-DM1; neutropenia is less prominent than with conventional cytotoxic chemotherapy
Emetogenicity Classification	Low
Monitoring Items	Platelet count and CBC, liver function tests (hepatotoxicity is a known class effect), left ventricular ejection fraction (cardiac monitoring due to the trastuzumab antibody component)
Handling Protection	Yes — as a cytotoxic conjugate, standard hazardous drug handling/reconstitution precautions should be followed

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic rationale is sound — PR-positive tumors that co-express HER2 already fall within T-DM1’s established therapeutic mechanism — but the automatically retrieved evidence base is only moderate quality (L3) and includes at least one mismatched trial that does not actually use T-DM1, so this should not yet be treated as a validated, independent new indication.

To proceed, the following is needed:

DrugBank MOA data and official approved-indication text (currently data gaps, including the blocking TFDA/local label warnings gap noted in the evidence pack)
Manual re-review of the four retrieved trials to confirm which genuinely test T-DM1 in a PR-positive (vs. HR-negative or HER2-low) population
A dedicated subgroup analysis or trial specifically powered on PR status, rather than relying on HER2-positive trials that only incidentally report PR status
Local safety and drug-interaction data before any market-facing communication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.